Stockreport

Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial

Summit Therapeutics Inc.  (SMMT) 
Last summit therapeutics inc. earnings: 6/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: summitplc.com/investors/investor-centre
PDF Increase in Utrophin Protein Expression ObservedSummit Accelerating Preparations for Pivotal Clinical TrialEzutromid is a Potential Disease-Modifying Treatment for the E [Read more]